Browse Negotiations Image Banner

Banner Text Velit velaliquam, ultricies eros dolore magna in in doming ullamco sint. Sint doming dignissim in quis pariatur consequat urna eu providerent. Sint dolore ea urna velit doming ea pulvinar.

General Callout

Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.

Accordion

Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.

Heading 1

Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.

Heading 2

Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.

Related content

Dolor commodo suscipit adipiscing suscipit, elit dolore velit. Amet tempuribud velit pariatur ullamco exercitation esse dolore sint velaliquam adipiscing eu pulvinar doming sunt, dignissim velit voluptate ex suscipit sunt ex, duis dignissim nunc tempuribud laboris commodo velit ut. Velit in harmud quis voluptate esse nulla.

Shop Now!

Laboris quis consectetur sed eros velit tempuribud suscipit magna ea consequat laboris. Elit adipiscing quis sunt duis magna nulla velit amet elit ex providerent consectetur tempuribud amet ex commodo urna, magna adipiscing elit sed duis nisi pulvinar, doming pariatur velaliquam quis providerent fugiat ea aliquip sit ut nisi sunt pulvinar eu velit.

grey rec centre

Call to action

Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate

Primary Button Secondary Button

Search by drug, manufacturer, or indication

Displaying 961 - 970 of 1165

Imbruvica (ibrutinib)

Status:

Concluded with an LOI

Manufacturer:

Janssen Inc.

Indication:

Mantle Cell Lymphoma

Last updated June 27, 2017

Neupro (rotigotine)

Status:

Concluded with an LOI

Manufacturer:

UCB Canada Inc.

Indication:

Parkinson's disease

Last updated June 23, 2017

Brenzys (etanercept)

Status:

Concluded with an LOI

Manufacturer:

Merck Canada Inc.

Indication:

Rheumatoid Arthritis and Ankylosing Spondylitis

Last updated June 19, 2017

Lenvima (lenvatinib)

Status:

Concluded with an LOI

Manufacturer:

Eisai Limited

Indication:

Differentiated Thyroid Cancer

Last updated June 16, 2017

XigDuo (dapagliflozin/metformin hydrochloride)

Status:

Concluded with an LOI

Manufacturer:

AstraZeneca Canada Inc.

Indication:

Diabetes Mellitus, Type 2

Last updated June 13, 2017

Mozobil (plerixafor)

Status:

Concluded with an LOI

Manufacturer:

Sanofi-Aventis Canada Inc.

Indication:

Non-Hodgkin's Lymphoma and Multiple Myeloma

Last updated June 6, 2017

Rituxan SC (rituximab)

Status:

Concluded with an LOI

Manufacturer:

Hoffmann-La Roche Ltd.

Indication:

Acute Lymphoblastic Leukemia (ALL)

Last updated May 24, 2017

Humira (adalimumab)

Status:

Concluded with an LOI

Manufacturer:

AbbVie Corporation

Indication:

Ulcerative Colitis

Last updated May 23, 2017

Vectibix (panitumumab)

Status:

Concluded with an LOI

Manufacturer:

Amgen Canada Inc.

Indication:

Metastatic Colorectal Cancer

Last updated May 22, 2017

Cotellic - Zelboraf (cobimetinib - vemurafenib)

Status:

Concluded with an LOI

Manufacturer:

Hoffmann-La Roche Ltd.

Indication:

Metastatic Melanoma

Last updated May 11, 2017